FDA clears first prescription digital app named Rejoyn to treat Depression nextdigitalhealth.com

FDA clears first prescription digital app named Rejoyn to treat Depression

Food and Drug Administration (FDA) has approved the first-ever “prescription digital therapeutic” smartphone app, Rejoyn, designed to aid in the treatment of major depressive disorder (MDD). Developed by Otsuka America Pharmaceutical, Rejoyn is intended to be used alongside traditional antidepressant medication and talk therapy, serving as an innovative adjunctive treatment for individuals struggling with MDD symptoms.

https://nextdigitalhealth.com/news/fda-clears-first-prescription-digital-app-named-rejoyn-to-treat-depression/